Cyclo Therapeutics, Inc.
CYTHNASDAQHealthcare
$0.72
+$0.00(+0.00%)
Market Cap$23589778
P/E Ratio—
52W High$1.6199
52W Low$0.55
Cyclo Therapeutics, Inc. (CYTH) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CYTH · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2024Report Date: Nov 14, 2024EPS Actual
-$0.26
Est. -$0.17 · -52.9%
Revenue
$0.00B
Est. $0.00B · -27.4%
Fiscal Period
Q4 FY2024
FY ends December
Report Date
Nov 14, 2024
After Market Close
▼ Miss EPS▼ Miss Revenue
CYTH reports quarterly as a NASDAQ-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q1 FY2025 | Mar 24, 2025 | -$0.17 | — | — | — | — | — |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$0.17 | -$0.26 | -52.9% | $0.00B | $0.00B | -27.4% |
| ▼ Q3 FY2024 | Aug 14, 2024 | -$0.14 | -$0.21 | -50.0% | $0.00B | $0.00B | -54.4% |
| ▲ Q2 FY2024 | May 15, 2024 | -$0.20 | -$0.15 | +25.0% | $0.00B | $0.00B | -59.1% |
| ▼ Q1 FY2024 | Mar 18, 2024 | -$0.21 | -$0.23 | -9.5% | $0.00B | $0.00B | -27.6% |
| ▼ Q4 FY2023 | Nov 14, 2023 | -$0.27 | -$0.29 | -7.4% | $0.00B | $0.00B | +15.2% |
| ▲ Q3 FY2023 | Aug 15, 2023 | -$0.44 | -$0.33 | +25.0% | $0.00B | $0.00B | -36.0% |
| ▼ Q2 FY2023 | May 15, 2023 | -$0.42 | -$0.46 | -9.5% | $0.00B | $0.00B | -59.9% |
Q1 FY2025
Mar 24, 2025
EPS Actual
—
EPS Est.
-$0.17
EPS Surpr.
—
Revenue
—
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$0.26
EPS Est.
-$0.17
EPS Surpr.
-52.9%
Revenue
$0.00B
Q3 FY2024
Aug 14, 2024Miss
EPS Actual
-$0.21
EPS Est.
-$0.14
EPS Surpr.
-50.0%
Revenue
$0.00B
Q2 FY2024
May 15, 2024Beat
EPS Actual
-$0.15
EPS Est.
-$0.20
EPS Surpr.
+25.0%
Revenue
$0.00B
Q1 FY2024
Mar 18, 2024Miss
EPS Actual
-$0.23
EPS Est.
-$0.21
EPS Surpr.
-9.5%
Revenue
$0.00B
Q4 FY2023
Nov 14, 2023Miss
EPS Actual
-$0.29
EPS Est.
-$0.27
EPS Surpr.
-7.4%
Revenue
$0.00B
Q3 FY2023
Aug 15, 2023Beat
EPS Actual
-$0.33
EPS Est.
-$0.44
EPS Surpr.
+25.0%
Revenue
$0.00B
Q2 FY2023
May 15, 2023Miss
EPS Actual
-$0.46
EPS Est.
-$0.42
EPS Surpr.
-9.5%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-0.22 | $-0.22 | $-0.22 | 1 |
| Q3 FY2025 | $-0.21 | $-0.21 | $-0.21 | 1 |
| Q2 FY2025 | $-0.22 | $-0.22 | $-0.22 | 1 |
| Q1 FY2025 | $-0.19 | $-0.19 | $-0.19 | 1 |
| Q4 FY2024 | $-0.12 | $-0.12 | $-0.12 | 2 |
| Q3 FY2024 | $-0.18 | $-0.16 | $-0.14 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q4 FY2024 | Nov 14, 2024 | -52.9% | $0.72 | $0.61 | -14.62% |
| ▼ Q3 FY2024 | Aug 14, 2024 | -50.0% | $1.17 | $1.19 | +1.71% |
| ▲ Q2 FY2024 | May 15, 2024 | +25.0% | $1.41 | $1.43 | +1.42% |
| ▼ Q1 FY2024 | Mar 18, 2024 | -9.5% | $1.65 | $1.60 | -3.03% |
| ▼ Q4 FY2023 | Nov 14, 2023 | -7.4% | $1.46 | $1.47 | +0.68% |
| ▲ Q3 FY2023 | Aug 15, 2023 | +25.0% | $1.46 | $1.34 | -8.22% |
| ▼ Q2 FY2023 | May 15, 2023 | -9.5% | $1.21 | $1.06 | -12.40% |
| ▼ Q1 FY2023 | Mar 20, 2023 | -336.0% | $1.11 | $0.94 | -15.32% |
Q4 FY2024-14.62%
Report Date
Nov 14, 2024
EPS Beat/Miss
-52.9%
Price Before
$0.72
Price After
$0.61
Q3 FY2024+1.71%
Report Date
Aug 14, 2024
EPS Beat/Miss
-50.0%
Price Before
$1.17
Price After
$1.19
Q2 FY2024+1.42%
Report Date
May 15, 2024
EPS Beat/Miss
+25.0%
Price Before
$1.41
Price After
$1.43
Q1 FY2024-3.03%
Report Date
Mar 18, 2024
EPS Beat/Miss
-9.5%
Price Before
$1.65
Price After
$1.60
Q4 FY2023+0.68%
Report Date
Nov 14, 2023
EPS Beat/Miss
-7.4%
Price Before
$1.46
Price After
$1.47
Q3 FY2023-8.22%
Report Date
Aug 15, 2023
EPS Beat/Miss
+25.0%
Price Before
$1.46
Price After
$1.34
Q2 FY2023-12.40%
Report Date
May 15, 2023
EPS Beat/Miss
-9.5%
Price Before
$1.21
Price After
$1.06
Q1 FY2023-15.32%
Report Date
Mar 20, 2023
EPS Beat/Miss
-336.0%
Price Before
$1.11
Price After
$0.94
Avg Beat Reaction-3.40%
Avg Miss Reaction-7.16%
Beat Rate2 / 8 quarters
Largest Move-15.32% (Q1 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CYTH ends December
Cyclo Therapeutics, Inc. (CYTH) most recently reported earnings on November 14, 2024 for Q4 FY2024, posting EPS of $-0.26 — missing the analyst consensus of $-0.17 by -52.9%. The next CYTH earnings date is expected around September 1, 2026.
Each quarter, investors track CYTH earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CYTH revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CYTH's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CYTH earnings · 5 questionsCyclo Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. CYTH typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CYTH historically reports after market close (AMC).
CYTH earnings datewhen is CYTH earningsCYTH next earnings datewhen does CYTH report earningsCYTH earnings calendar
▸ Source: FMP · Cyclo Therapeutics, Inc. SEC filings · US GAAP · Cyclo Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026